// App-Quantinova.ai

TPS5070 : Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

Researchers

Presenter

  • Nicholas J. Vogelzang

Principal Investigators

  • Tomasz M. Beer

  • Jirina Bartunkova

  • William K. Oh

  • Stephane Oudard

  • Hardev S. Pandha

  • A. Oliver Sartor

  • Radek Spisek

  • Niels Geert Borgstein

  • Winald R. Gerritsen

  • Rostislav Kuklk

  • Kurt Miller

Medical Centers

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Carolina Urologic Research Center, The US Oncology Network, Myrtle Beach, SCUniversity of Surrey, Surrey, United KingdomDivision of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Charite-University Medicine Berlin, Berlin, Germany

  • Tulane Cancer Center, New Orleans, LA

  • Georges Pompidou Hospital, Paris, France

  • SOTIO a.s., Prague, Czech Republic

  • Radboud University Medical Center, Njmegen, Netherlands

Locations

  • Czech Republic

  • Netherlands

  • Germany

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Prednisone

  • Docetaxel

  • DCVAC/PCa

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved